All In Biotech

Drug Trial Radar · NCT00570765

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis

Last checked: Nov 19, 2026Latest source record: Jun 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

Jan 17, 2008

Primary completion

Sep 21, 2010

Study completion Sep 25, 2017

Sponsor

Lead sponsor
Intercept PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Dec 11, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary hypothesis was that obeticholic acid (OCA) will cause a reduction in alkaline phosphatase levels in PBC participants, over a 12-week treatment period, as compared to placebo.

Conditions

  • Liver Cirrhosis, Biliary

Interventions

  • PlaceboDrug

    Matching placebo tablets were administered orally once daily.

  • Obeticholic Acid (OCA)Drug

    Starting dose of 10 or 50 mg administered orally once daily, followed by dose titration planned from 10 mg to 25 mg to 50 mg once daily, which could be modified for safety and tolerability issues or to achieve adequate therapeutic response.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DB Phase: Mean Percent Change In Serum Alkaline Phosphatase (ALP) From Baseline To Day 85Time frame: Baseline, Day 85

Locations

21 sites in 7 countries. Site status is shown where the registry gives one.

  • Henry Ford

    Detroit, Michigan

  • Baylor College of Medicine

    Houston, Texas

  • Virginia Commonwealth University

    Richmond, Virginia

  • Virginia Mason Medical Center

    Seattle, Washington

  • Karls-Franzens University

    Graz, Austria

  • University of Alberta

    Edmonton, Alberta, Canada

  • University of Toronto

    Toronto, Ontario, Canada

  • Centre de Recherche du CHUM / University of Montreal

    Montreal, Quebec, Canada

  • Hopital de l'Hotel Dieu

    Lyon, France

  • Hopital Saint-Antoine

    Paris, France

  • Johann Wolfgang Goethe University

    Frankfurt, Germany

  • University Medical Centre Hamburg-Eppendorf

    Hamburg, Germany

  • Medical School of Hannover

    Hanover, Germany

  • University of Munich

    Munich, Germany

  • Hospital Clinic i Provincial

    Barcelona, Spain

  • Royal Infirmary

    Edinburgh, United Kingdom

  • Sunderland Research Ethics Committee

    Jarrow, United Kingdom

  • University Upon Tyne/Newcastle

    Newcastle upon Tyne, United Kingdom

  • Queen Elizabeth Medical Center

    Edgbaston, Birmingham, United Kingdom

  • Royal Free Hospital

    Hampstead, London, United Kingdom

  • John Radcliffe Hospital

    Headington, Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.